David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opening Session Panel Discussion

Jul

Today In Oncology

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opening Session Panel Discussion

Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma

Women Aged 65 Plus Still at Heightened Risk of HPV-Related Cervical Cancer

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

Optimizing the CAR to the Disease in B-Cell Malignancies

Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk